http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : D. Martel (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
I.V. Kityk,H. Nguyen Cong,D. Martel,M. Piasecki,K. Ozga,J. Ebothe 한국물리학회 2009 Current Applied Physics Vol.9 No.5
In the present paper for the first time we study the influence of simultaneous polarized optical treatment (10 ns Nd: YAG lasers with power density 0.6 GW/㎠) together with electrostatic dc electric field (up to 8 kV/cm) on self-assembled multi-layer films samples. The second-order optical susceptibility (SOS) achieves the maximal values after one minute simultaneous dc-electrical-optical treatment. Further treatment will not enhance the values and even leads to the decrease of SOS. The independent measurement of the local temperature shows that local heating do not excess 8.6 K.
-
Pharmacological Treatment of Degenerative Cervical Myelopathy: A Critical Review of Current Evidence
Jordan J. Levett,Miltiadis Georgiopoulos,Simon Martel,Wissam Al Mugheiry,Nikolaos A. Stavropoulos,Miguel Vega-Arroyo,Carlo Santaguida,Michael H. Weber,Jeff D. Golan,Peter Jarzem,Jean A. Ouellet,Georgi 대한척추신경외과학회 2024 Neurospine Vol.21 No.2
Degenerative cervical myelopathy (DCM) is the leading cause of spinal cord dysfunction in adults, representing substantial morbidity and significant financial and resource burdens. Typically, patients with progressive DCM will eventually receive surgical treatment. Nonetheless, despite advancements in pharmacotherapeutics, evidence for pharmacological therapy remains limited. Health professionals from various fields would find interest in pharmacological agents that could benefit patients with mild DCM or enhance surgical outcomes. This review aims to consolidate all clinical and experimental evidence on the pharmacological treatment of DCM. We conducted a comprehensive narrative review that presents all pharmacological agents that have been investigated for DCM treatment in both humans and animal models. Riluzole exhibits effectiveness solely in rat models, but not in treating mild DCM in humans. Cerebrolysin emerges as a potential neuroprotective agent for myelopathy in animals but had contradictory results in clinical trials. Limaprost alfadex demonstrates motor function improvement in animal models and exhibits promising outcomes in a small clinical trial. Glucocorticoids not only fail to provide clinical benefits but may also lead to adverse events. Cilostazol, anti-Fas ligand antibody, and Jingshu Keli display promise in animal studies, while erythropoietin, granulocyte colony-stimulating factor and limaprost alfadex exhibit potential in both animal and human research. Existing evidence mainly rests on weak clinical data and animal experimentation. Current pharmacological efforts target ion channels, stem cell differentiation, inflammatory, vascular, and apoptotic pathways. The inherent nature and pathogenesis of DCM offer substantial prospects for developing neurodegenerative or neuroprotective therapies capable of altering disease progression, potentially delaying surgical intervention, and optimizing outcomes for those undergoing surgical decompression.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
